INTRODUCTION
Management of atherosclerotic renovascular disease (ARVD) continues to be plagued with confusion. Although many clinicians favor attempting balloon angioplasty for younger hypertensive patients with fibromuscular dysplasias, an array of prospective, randomized clinical trials (RCTs) for atherosclerotic disease up to now have failed to demonstrate additional benefits from restoring renal artery patency when added to optimal medical therapy. Hence, endovascular revascularization procedures for ARVD have fallen substantially over the last decade. These trial data are at odds with clinical experience and adverse outcomes after renal artery occlusion reported for some patients [1, 2] . Additional reports identify specific high-risk patient subgroups with major clinical benefits with revascularization [3 & , 4, 5 && ]. Some authors and specialty groups have weighed in with opinions regarding 'appropriate use' of renal artery stenting [6 & ,7] . In this review, we will summarize recent publications in this field, including emerging perspectives on the status of the poststenotic kidney, evaluation of the RCTs to date, and specific clinical instances where intervening to restore renal circulation is of clear benefit.
VASCULAR OCCLUSIVE DISEASE AFFECTING THE KIDNEY
Unquestionably, renovascular disease can activate pressor pathways leading to accelerated hypertension. One must recognize, however, that atherosclerosis is a systemic disorder characterized by the activation of multiple inflammatory pathways. Studies of vessels in patients with early ARVD indicate disturbances in both tissue and circulating inflammatory cell types, even before hypertension or parenchymal kidney injury are apparent [8] . Recent studies also implicate immune mechanisms in driving experimental hypertension and its target manifestations [9] . Although the prevalence of ARVD continues to rise with age and associated atherosclerotic disease, occasional reports appear in adolescent study participants with severe risk factors, including genetic dyslipidemias [10] . Although most ARVD lesions are of minor hemodynamic significance, some progress to produce a spectrum of clinical manifestations that eventually includes renovascular hypertension, accelerated cardiovascular morbidity, circulatory congestion and parenchymal renal functional deterioration (Fig. 1) . Multiple observational and registry studies in the past suggest that renal revascularization can lead to improved blood pressure control, although it rarely reverses hypertension completely in ARVD. A recent report from the Herculink Elite Renal Stent to treat Renal Artery Stenosis (HERCULES) investigators reconfirms this point, indicating that 202 patients experienced SBP reduction from 162 AE 18 to 146 AE 16 mmHg (P < 0.001) after 36 months with no changes in medications [11 & ]. These authors argue that the selection of patients with treatment resistant hypertension (more than 70% were uncontrolled on three or more medications) led to sustained, clinically important blood pressure reduction. Few features specifically related to the degree of vascular occlusion actually predict the blood pressure response to revascularization. Studies of temporary balloon occlusion indicate that a translesional gradient of at least 10-20% between aortic pressures and postlesional renal artery pressure is required for measurable activation of the rennin-angiotensin system [12] , long an established major component underlying renovascular hypertension [13] . The degree of 'hyperemic systolic gradient' induced by dopamine or other agents has been proposed as a predictor of pressure response after revascularization [14] . These observations are particularly important as results from prospective RCTs in patients with ARVD indicate that the degree of stenosis is frequently overestimated, even in experienced catheterization laboratories [15 && ]. Review of ARVD lesions by the angiographic core laboratory for Cardiovascular Outcomes for Renal Atherosclerotic Lesions (CORAL) for 239 'roll-in' patients' downgraded estimates of stenosis from 73% lesion occlusion to 66% on average, leaving fewer than 20% of study participants in this trial with occlusive lesions above 80%. In this trial, the correlation between severity of vascular stenosis and translesional pressure gradients was low (r ¼ 0.21, P ¼ 0.06) [16] . As many authors have observed, the hemodynamic properties of the renal vessels are not
KEY POINTS
Prospective RCTs enrolling relatively low-risk patients fail to demonstrate major additional benefits from renal revascularization. Most patients are now treated initially primarily with medical therapy.
Studies of vascular stenosis and injury within the poststenotic kidney indicate a progression from hemodynamic compromise to inflammatory and fibrotic injury.
Numerous clinical observations reinforce the benefit of renal revascularization in specific 'high-risk' subsets that develop clinical manifestations despite medical management.
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"incidental RAS" Accelerated cardiovascular disease congestive heart failure stroke Ischemic nephropathy FIGURE 1. Spectrum of atherosclerotic renovascular disease; clinical manifestations vary considerably depending in part on the severity of vascular occlusion, but also the state of the underlying kidney. Although many lesions are of minor hemodynamic importance, prolonged and severe vascular occlusion accelerates hypertension, circulatory congestion and ultimately threatens viability of the kidney. Reproduced with permission [3] . RAS, renal artery stenosis.
the sole determinant of clinical manifestations related to ARVD [17] . Medical therapy for renovascular hypertension has become more standardized and effective. Although activation of the rennin-angiotensin system has long been recognized as central to the initiation of renovascular hypertension, application of agents to block this system, specifically angiotensin converting enzyme inhibitors and angiotensin receptor blockers, has been inconsistent, likely due in part to concerns about the potential fall in glomerular filtration pressures because of the removal of efferent vascular effects of angiotensin within the kidney. Investigators from the CORAL trial examined the prevalent use of renin-angiotensin blockade prior to randomization in 853 of 931 trial participants [18 && ]. Overall, 49% of study participants had been treated with these agents before entering CORAL. A lower number than average was observed in those with preexisting chronic kidney disease [estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m 2 ] and a higher proportion in those with preexisting diabetes. Importantly, patients treated with rennin-angiotensin blockade had lower SBP (148 AE 23 vs. 152 AE 23, P ¼ 0.003) and were more likely to have reached goal BP (30 vs. 22% P ¼ 0.01). After enrollment in CORAL, all participants were administered renninangiotensin blockade, specifically to address whether renal revascularization provides additional benefits beyond removing the effects of the renninangiotensin system. In both CORAL and Angioplasty and STenting for Renal Atherosclerotic Lesions, overall goal pressures were achieved in remarkably high proportions of the groups treated with or without revascularization [15 && ]. Aggressive use of statins and glycemic control were also benchmarks of the CORAL population. Although some patients cannot tolerate rennin-angiotensin blockade without deteriorating renal function, this was infrequent in the prospective trials and previously reported registry data [19, 20] . A major conclusion from the prospective RCT's must be that current medical therapy can be remarkably effective for many patients with ARVD.
Wider application of endovascular aortic stent grafts sometimes is associated with a clinical syndrome of iatrogenic renal artery stenosis, as these grafts can migrate or be placed across the renal arteries. A prospective RCT reporting results of a fenestrated endovascular graft in 67 patients indicated that 129 renal vessels were targeted by fenestration at the time of placement. Four developed renal artery occlusion and 12 developed significant stenosis. A total of 15 patients (22%) required secondary interventions for renal artery stenosis/occlusion [21 && ].
CONDITION OF THE POSTSTENOTIC KIDNEY
An important corollary of improved medical management of renovascular hypertension is the fact that most ARVD remains in place for long periods of time before being identified and considered for revascularization. The kidney can tolerate moderate reductions in blood flow without developing either tissue hypoxia or identifiable tissue injury. In part this reflects the balance between blood flow (and therefore oxygen supply) and reduced oxygen consumption that follows reduced filtration [22] . These observations reinforce the conclusion that antihypertensive drug therapy to lower systemic pressures can be tolerated without progressive loss of renal function over prolonged periods of time, sometimes for years. As a result, many patients in the treatment trials had stable kidney function despite substantially reduced renal perfusion pressures. Experimental and clinical studies indicate that beyond certain limits, however, vascular occlusive disease does reduce renal cortical oxygenation, activating renal inflammatory pathways, oxidative stress and tissue fibrosis [23] . Measurement of renal vein effluent levels of neutrophil gelatinase-associated lipocalin suggest that pro-inflammatory signaling pathways persist even after restoring renal blood flow in human study participants [24] and may affect both poststenotic and nonstenotic contralateral kidneys with a shift toward metabolomics profiles associated with chronic kidney disease [25] . Transjugular biopsy specimens from the poststenotic kidney demonstrate appearance of both CD-3 þ T cells and CD-68
]. These changes are associated with interstitial inflammation, loss of viable tubular structures and glomerular obsolescence. Experimental studies in acute ischemic injury suggest that the polarity of macrophages within the postischemic kidney is an important determinant of recovery after restoring blood flow and that failure to transition to the reparative (M-2) phenotype is associated with failure to regenerate tubules and progression to chronic kidney disease [27 && ]. Human kidneys are unusually tolerant to some forms of ischemic injury. Unlike experimental models in which severe tubular necrosis develops after 30-45 min, a study of human kidney tissue obtained during total isolated renal artery occlusion for 30-60 min demonstrated few histologic changes or biomarker evidence of injury biomarker release or clinical acute kidney injury [28] . An early sign of ischemic injury in this study was distortion of mitochondrial structures. Application of mitochondrial protection peptides in ischemic models accelerates adenosine triphosphate (ATP) 30] . These studies provide evidence that targeted stabilization of cardiolipin within mitochondrial structures stabilizes the electron transport chain, allowing the preservation of ATP production and minimizing the release of toxic oxygen species in a variety of organs, including kidney, muscle, heart, and brain. Importantly, studies of renovascular swine models treated with mitochondrial protection agents indicate that weekly injections reduce oxidative stress and fibrosis, improve vascular density and tissue oxygenation, and prevent the loss of GFR [31 & ]. Previous studies indicated that administration of mitochondrial protection agents at the time of restoring renal blood flow with endovascular procedures improves renal functional outcomes [32] .
Prolonged hemodynamic compromise does activate inflammatory pathways within the kidneys. Measurement of renal vein cytokines indicates ongoing net release of proinflammatory markers, including IL-10 and TNFa, both in humans and experimental models [24, 33] . Restoring blood flow with endovascular procedures fails to reverse this process, but administration of adipose-derived mesenchymal stem cells in experimental ARVD can reduce cytokine release and reduced tissue markers of inflammatory injury [33] . Whether such maneuvers can modify human renal tissue inflammatory injury remains to be seen.
Taken together, these studies indicate that ARVD undergoes a transition from purely hemodynamic compromise limiting kidney function to a condition of ongoing parenchymal injury that includes oxidative injury, inflammation, and ultimately fibrosis. (Fig. 2) . Clinical studies directed toward both mitochondrial protection and adjunctive therapy with mesenchymal stromal/stem cells are in progress (Clinicaltrials.gov). How best to define the state of the kidney, both to restore blood flow and recover kidney function before irreversible injury ensues, remains a major challenge for clinicians.
WHEN TO PURSUE RENAL REVASCULARIZATION
The selection of patients for vascular intervention obviously depends on the likelihood of obtaining some clinical benefit. Considering the complexity of factors regulating blood pressure and kidney function outlined above, this is rarely straightforward. Paradoxically, the likelihood of clinical benefit regarding blood pressure control (and possibly renal function as well) is highly related to the duration of manifest ARVD. Hence, those with shorter duration of overt renovascular hypertension are most likely to lower arterial pressure after revascularization. Multiple predictive clinical features were examined for unilateral atherosclerotic disease in a publication from Italy [34 && ] based on a single-center experience over the years between 1990 and 2008. They report that baseline levels of kidney function (eGFR by modification of diet in renal disease) in 158 patients analyzed were lower (eGFR 45 vs. 63 ml/min/ 1.73 m 2 , P < 0.05) in those without renal functional recovery. Ultrasound derived measures of resistive index defined as [(peak systolic velocity -enddiastolic velocity)/peak systolic velocity] were independent predictors of actual recovery of eGFR (defined as an increase more than 20% of baseline eGFR), even after adjusting for age, sex, obesity, and baseline serum creatinine above 1.8 mg/dl. In general agreement with previous reports, resistive index within the contralateral kidney (using a cutpoint of 0.73, somewhat lower than 0.8 as others have proposed) was the best single predictor of functional outcome, possibly as it defined the state of the parenchymal small vessels within the kidney not directly subject to large vessel disease. Thirty-six of 158 (22.8%) treated patients had identifiable increases in eGFR over 12 months. Importantly, no ultrasound parameters predicted the response of blood pressure, reinforcing the separation of blood pressure regulation from kidney function in ARVD.
The technical aspects of endovascular revascularization continue to improve. In the series from Italy of 158 patients, major complications affecting the kidney (three leading to nephrectomy, one arterial thrombosis, and 1 restenosis) were infrequent. Retroperitoneal bleeding and partial renal ischemia from branch occlusion developed in five additional patients for a complication rate of 6.3%. Reported complications in the CORAL trial identified and corroborated by the angiographic core laboratory were infrequent, in total 2.2% in the (a) Serum creatinine, blood pressure and medications over an 8-year period in a patient with unilateral atherosclerotic renovascular disease associated with a nonfunctioning kidney (<5% by renal scan). This patient developed severe hypertension that responded well to a regiment based upon an angiotensin receptor blocker (valsartan). Several years later, however, she developed worsening renal failure with an eGFR ¼ 16 ml/min/1.73 m 2 , leading to evaluation for kidney transplantation. Her disease was managed conservatively, but she developed severe hypertension and worsening renal function (creatinine above 5.0 mg/dl), leading her physician to withhold the angiotensin receptor blockers. Serum creatinine fell, although blood pressure was difficult to control and she developed episodes of acute pulmonary edema. (b) Doppler ultrasound identified a stenosis to her remaining functional kidney (peak systolic velocity above 500 cm/s). This was treated with endovascular stenting, with marked improvement in blood pressure levels, stable kidney function and tolerance to restarting the angiotensin receptor blocker (valsartan). BP, blood pressure; eGFR, estimated glomerular filtration rate; RAS, renal artery stenosis.
main arm of the trial. This was in contradistinction to the 'roll-in' phase of the trial where 239 patients were evaluated by the angiographic core. In this group, 13% (n ¼ 28) experienced 'major' angiographic complications, including dissection (n ¼ 11; 4.5%), embolus (n ¼ 9; 3.7%), occlusion (n ¼ 9; 3.7%), thrombus (n ¼ 3; 1.2%), vessel rupture (n ¼ 2; 0.8%), wire perforation of a branch artery (n ¼ 2; 0.8%), and pseudoaneurysm (n ¼ 1; 0.4%) [16] . Many of the initial complications were attributed to the concurrent use of a large distal protection device (Angioguard) initially required for the trial. Development of this device was discontinued and not utilized for the main portion of CORAL. Results 3 years after enrollment for 202 patients treated with the HERCULES cobalt/chromium stent specifically designed for the renal artery confirmed 'procedural success' (stent deployment) in more than 99% of arteries [11 & ]. Restenosis after 9 months was 22/209 (10.5%). Long-term blood pressure levels were maintained well below enrollment levels (74% had meaningful step-down in pressure levels) without change in medications. The complication rate for 30 days was 1.5%. Taken together, endovascular stent procedures in experienced laboratories is reasonably safe.
EVIDENCE-BIASED MEDICINE?
In the current milieu, RCT data are considered by some to represent a form of 'gold-standard' evidence. Multiple proposed RCTs with atherosclerotic renal artery stenosis have been limited by poor recruitment, in part the result of previous clinical experience and lack of consensus. As a result, even carefully performed trials have been subject to selection bias for relatively low-risk participants [3 & ]. Although prospective RCTs in fact provide evidence for 'average participants' of large groups, such data may not apply to specific individuals with atypical features. Concluding that a 'negative trial' (e.g., one that fails to identify overall population benefit from renal revascularization) means that such therapy should be abandoned likely deprives specific, high-risk patients from major benefit. Reports of successful renal revascularization regularly provide examples of individuals with pivotal recovery of renal function or relief from pulmonary edema, most often in patients that were underrepresented in the relatively small, prospective trials conducted up to now. [1,2,5 && ]. An example of such a patient is illustrated in Fig. 3 , depicting creatinine values and BP information for over several years when the role of ARVD was overlooked for several years. This individual progressed to advanced renal failure, was listed for kidney transplant, and later developed episodes of 'flash pulmonary edema'. Remarkably, the solitary poststenotic kidney remained viable and both kidney function and refractory hypertension regressed after successful endovascular stenting. Table 1 illustrates a recent 'consensus' document published by the Society for Cardiovascular Angiography and Intervention that identifies clinical syndromes for which renal artery interventions may be considered 'appropriate use'.
CONCLUSION
Atherosclerotic renal artery stenosis presents a wide variety of clinical syndromes, many of which are managed initially with current medical therapy. Recent data highlight the transition from primarily a hemodynamic condition limiting renal blood flow to a complex inflammatory process in the kidney characterized by oxidative stress, inflammation and macrophage activation. Restoring vessel patency can interrupt this transition and may provide major benefits to high-risk patients, particularly when combined with investigational procedures to modify injury pathways. Identifying such patients in whom medical therapy is failing and for whom renal revascularization can stabilize circulatory control and renal function is the central challenge for clinicians.
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